Investors in Denali Therapeutics Inc. (NASDAQ:DNLI) had a good week, as its shares rose 9.6% to close at US$23.89 following the release of its quarterly results. Statutory losses were a bit smaller than expected, at just US$0.55 per share, even though revenues of US$3.6m missed analyst expectations by a shocking 21%. This is an important time for investors, as they can track a company’s performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We’ve gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

View our latest analysis for Denali Therapeutics

NasdaqGS:DNLI Past and Future Earnings May 10th 2020NasdaqGS:DNLI Past and Future Earnings May 10th 2020

Following

Read More At Article Source | Article Attribution